Drugs / GSK2820151
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02630251 | Apr 2016 → Dec 2018 | cancer | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2820151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02630251 ↗ |
| Action | Inhibit | “BET inhibitor” NCT02630251 ↗ |
| Route | Oral | “to be administered orally” NCT02630251 ↗ |